Figure 2.
Adjusted incidence (based on the fully balanced data in Table 3) of ischemic and bleeding events in clopidogrel-treated patients with different CYP2C19 phenotypes: poor (PM), intermediate (IM), normal (NM), rapid (RM), or ultrarapid (UM) metabolizer. Depicted are percentages from the weighted pseudopopulations.